|
|
|
03.09.25 - 22:09
|
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
LA JOLLA, Calif.--(BUSINESS WIRE)--#AhRModulation--Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on August 29, 2025, the Compensation Committee of Equillium's Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase an aggregate of 150,000 shares of common stock to two new employees under Equillium's 2024 Inducement Plan. The Compensation Committee approved the stock option as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price per share equal to $1.74, Equillium's closing stock price on August 29, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee's contin...
|
|
|
|
|
11.08.25 - 14:33
|
Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic (Business Wire)
|
|
|
Financing led by ADAR1 Capital Management and Janus Henderson Investors
$30 million up front with the potential to receive an additional $20 million at clinical study initiation
Phase 1 clinical study initiation planned mid-2026; data anticipated approximately 6 months thereafterLA JOLLA, Calif.--(BUSINESS WIRE)--#AhRModulation--Equillium, Inc. (“Equillium” or the “Company”) (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced it has entered into a definitive securities purchase agreement with leading healthcare investors that will provide up to $50 million in gross proceeds to Equillium. The private placement is comprised of (i) an initial upfront financing of approximately $30 million in gross proceeds in exchange for approximately 52.6 million shares of common stock (or, for certain investors, pre-funded warrants in lieu of common stock), representing a purchase price of $0.57 for each share of common stock sol...
|
|
|
|
|
06.05.25 - 14:09
|
Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists (Business Wire)
|
|
|
EQ504 protects against gut damage in a mouse model of ulcerative colitis
EQ504 increases Treg stability and function while suppressing pathogenic Th17 responses
EQ504 promotes healing of intestinal epithelial cells by promoting anti-inflammatory cytokines
LA JOLLA, Calif.--(BUSINESS WIRE)--$EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that three posters were presented at IMMUNOLOGY2025, the annual meeting of The American Association of Immunologists taking place at the Hawaiʻi Convention Center in Honolulu, Hawaii, May 3 – 7.
“Decades of independent research have validated AhR as an important physiological regulator of immune homeostasis in barrier tissues such as the gut,” said Dr. Stephen Connelly, chief scientific officer at Equillium. “These data demonstrate the potent activity of EQ504 in suppressing inflammation and...
|
|
|
|
|
|
|
|
|
27.03.25 - 12:06
|
Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights (Business Wire)
|
|
|
Announced topline data from the Phase 3 EQUATOR study in first-line acute graft-versus-host disease
Breakthrough Therapy designation and meeting request to discuss potential for Accelerated Approval submitted to FDA, feedback expected during May 2025
LA JOLLA, Calif.--(BUSINESS WIRE)--$EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the fourth quarter and full year 2024, as well as corporate and clinical highlights.
“This morning, following considerable efforts by our clinical team, we announced topline data from the Phase 3 EQUATOR study evaluating itolizumab in first-line treatment of acute graft-versus-host disease,” said Bruce Steel, chief executive officer at Equillium. “While we did not meet Day 29 outcomes of complete response - our primary endpoint - and overall response rate, itolizumab did ...
|
|
|
|
|
21.02.25 - 17:30
|
Here′s Why Equillium (EQ) Is a Great ′Buy the Bottom′ Stock Now (Zacks)
|
|
|
Equillium (EQ) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
